Organiser
Strategies
1.Introduction
The global anti-glycation market is experiencing rapid expansion, primarily driven by growing consumer awareness that glycation is a key driver of skin aging. This review introduces 'Anglysin IB', a novel anti-glycation ingredient extracted from Inula britannica flower, and elucidates its triple-core mechanism of anti-glycation action and clinical efficacy.
2.The Scientific Background of Skin Glycation
The purpose of "anti-glycation" is primarily to inhibit the formation and accumulation of Advanced Glycation End Products (AGEs) - stable covalent compounds formed by the non-enzymatic reaction between reducing sugars and proteins, lipids, or nucleic acids. This process is accelerated by exogenous factors like UV radiation and cigarette smoke, as well as endogenous factors including oxidative stress and inflammation. The accumulation of AGEs disrupts dermal proteins such as collagen and elastin, impairing skin's mechanical properties and contributing to a dull, sallow, and less elastic complexion.
3. In-depth Look at the Triple-core Anti-glycation Mechanism
Traditional anti-glycation strategies are often limited to a single pathway, such as inhibiting the formation of AGEs or regulating the RAGE receptor pathway, failing to comprehensively address the complex network of skin glycation. JAKA Biotech has deeply explored the pathways of glycation damage, breaking through the conventional approach of "single-point inhibition" and innovatively proposing a synergistic anti-glycation strategy: [1. Blocking, 2. Clearing, 3. Regulating]. This strategy not only validates traditional anti-glycation pathways but also incorporates the cutting-edge mechanism of "clearing."
In the [Clearing] phase, firstly, by upregulating soluble RAGE (sRAGE), it captures AGEs in the skin, preventing them from activating downstream damage effects. sRAGE is also referred to as the "AGEs scavenger." Secondly, it activates the autophagy pathway in fibroblasts, accelerating the clearance of intracellular AGEs. Traditionally, it was believed that once formed, AGEs could not be cleared. JAKA Biotech took the lead in targeting advanced clearing targets and pathways, and through scientific model verification, ultimately proved that generated AGEs can be cleared at the cellular level.
Furthermore, we are pioneers in introducing microRNA research into the field of skin glycation. Through transcriptome screening and literature analysis, we have for the first time discovered and confirmed that miRNA-145-5p is a key regulator in the processes of skin glycation and aging. The identification of this novel target not only provides genetic-level validation for the precise efficacy of Anglysin IB but also opens up new avenues for fundamental research on anti-glycation.
5. Clinical Efficacy: Validated 6-Dimensional Improvements
A clinical study on a formulation with 0.5% Anglysin IB demonstrated significant efficacy across 6 major dimensions over 56 days:
Anti-Glycation: AGEs values decreased significantly (-15.43% at D28; -17.42% at D56). Based on internal data fitting and conversion, it can be inferred that after 56 days of using test samples containing 0.5% Anglysin IB, glycation-induced aging was reversed by 4 years.
Skin Yellowing & Brightening: Significant reduction in skin yellowness (Δb*). Skin brightness (ITA°) increased by 26.68%, with a corresponding 3.09% reduction in melanin.
Anti-Wrinkle & Firming: Skin density increased by 26.69% (D14), and skin rebound time was reduced by 16.14% (D56), indicating improved firmness and elasticity.
Wrinkle Reduction: Visual assessments confirmed a reduction in the appearance of crow's feet and under-eye wrinkles.
6. Conclusion
In conclusion, Anglysin IB offers a scientifically validated and multi-targeted solution to skin glycation. Its proven efficacy directly addresses the demand for advanced anti-glycation skincare. This makes it ideal for consumers aiming to counteract skin dullness, yellowing, and elasticity loss caused by contemporary high-sugar diets and lifestyles.